Heart Failure Clinical Trial

Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial

Summary

To determine the effect of hawthorn extract 450 mg bid vs. placebo, in addition to standard medical therapy in ambulatory patients with NYHA class II to IV chronic heart failure on submaximal exercise as measured by the 6-minute walk test

View Full Description

Full Description

See Brief Summary

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Ambulatory individuals 18 years and older who had been diagnosed with CHF (NYHA functional classes II-IV) for > 3 months
Left ventricular ejection fraction (LVEF) of ≤ 40 percent
Receiving indicated standard therapy (if not contraindicated or intolerant for > 3 months) defined as a diuretic, an ACE-inhibitor or an angiotensin receptor blocker (ARB) and a beta-blocke
Patients with NYHA class III or IV symptoms were also required to receive spironolactone. Doses of these drugs had to be stable for ≥ 3 months, except for diuretics, for which ≥ 1 month of stability was required.

Exclusion Criteria:

Hemodynamically severe uncorrected primary valvular disease
Active myocarditis
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Myocardial infarction, stroke, unstable angina, coronary artery bypass graft surgery, valvular surgery, or angioplasty < 3 months before randomization
Symptomatic or sustained ventricular tachycardia not controlled by antiarrhythmic drugs or an implantable cardioverter-defibrillator
Any condition other than heart failure that would be expected to limit exercise (e.g., angina, peripheral vascular disease, pulmonary disease, arthritis, or an orthopedic problem severe enough to limit exercise)
Nursing mothers, pregnant women and those planning a pregnancy during the study period

Study is for people with:

Heart Failure

Phase:

Phase 3

Estimated Enrollment:

120

Study ID:

NCT00343902

Recruitment Status:

Completed

Sponsor:

National Center for Complementary and Integrative Health (NCCIH)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Michigan
Ann Arbor Michigan, 48104, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 3

Estimated Enrollment:

120

Study ID:

NCT00343902

Recruitment Status:

Completed

Sponsor:


National Center for Complementary and Integrative Health (NCCIH)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider